From Investing.com:

BioArctic AB and partner Eisai have received approval for Leqembi in China for treating mild cognitive impairment and mild dementia due to Alzheimer’s disease. This makes China the third country to approve the drug, after the US and Japan. Leqembi targets amyloid-beta aggregates and has been shown to slow disease progression. Eisai plans to launch the drug in China in Q3 2024, with an estimated 17 million affected patients.

Eisai’s Leqembi has been approved in China for the treatment of mild cognitive impairment and mild dementia due to Alzheimer’s disease. The drug targets amyloid-beta aggregates and has been shown to slow cognitive and functional decline in patients. The approval in China is based on positive results from the Phase 3 Clarity AD study.

Eisai is preparing to launch Leqembi in China in the third quarter of 2024, with an estimated 17 million patients affected by MCI or mild dementia due to Alzheimer’s disease in the country. The company plans to distribute the product, engage in awareness activities, and improve diagnostic environments, including the use of blood-based biomarkers to detect the disease.

BioArctic, collaborating with Eisai, will receive royalties on global sales of Leqembi and is entitled to commercialize the drug in the Nordic region pending European approval. The company will not incur development costs and is entitled to receive payments for regulatory approvals and sales milestones.

This article contains information based on a press release from BioArctic AB and has been supported by AI and reviewed by an editor.



Read more: China approves Leqembi for Alzheimer’s treatment By Investing.com